

Interleukin-2, a Tale of Two Halves: To Suppress or Augment Suppression, That is the Question

<https://marketpublishers.com/r/I5AE2F910EDEN.html>

Date: May 2019

Pages: 17

Price: US\$ 1,250.00 (Single User License)

ID: I5AE2F910EDEN

Abstracts

Report Includes:

An introduction to interleukin-2 (IL-2) and identification of its applications

Insights into the latest trends and technologies in the IL-2 research and development

Discussion of strategies adopted by IL-2 developers for the successful treatment of cancer and information on NKTR-214, a Nektar Therapeutics product

Review of recent VC investment in this zone highlighted by Syncona and Novartis Venture Fund recent CHF35m investment in Anaveon AG, a new Swiss Biotech company spun out from the University of Zurich which is developing a novel oncologic monoclonal antibody that boosts IL-2 but has an improved side-effect profile

Detailed description of autoimmune responses and possible ways to augment immune responses so as to improve antitumor activity and reduce off target effect

An understanding of various conditions which may develop as an off-target effects in the cancer treatment such as metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse remitting multiple sclerosis (RRMS), and Type 1 diabetes (T1D)

Contents

CHAPTER 1 INTRODUCTION

Introduction

Interleukin-2 an Important Driver for T Cell Homeostasis

Analyst's Credentials

Related BCC Research Reports

CHAPTER 2 A BALANCING ACT

Targeted Effects

Off-Target Effects

CHAPTER 3 APPROVED IL-2 THERAPIES

IL-2 Antagonist Immunosuppressant

Simulet (Basiliximab) Novartis

Zenapax (Daclizumab) Roche

Zinbryta (Daclizumab) AbbVie/Biogen

Leukotac (Iolimomab) ElsaLys Biotech

IL-2 Agonist Cancer Immunotherapy

Proleukin (Aldesleukin) Novartis/Chiron

CHAPTER 4 FUTURE OPPORTUNITIES

New Strategies to Harness IL-2's Potential

IL-2 Monoclonal Antibodies

IL-2 Antibody Drug Conjugates

IL-2 Antibody?Cytokine Fusion Proteins

IL-2 Mutant Superkines

IL-2 Therapeutic Protein Inhibitor

IL-2 Immunotoxins

IL-2 Radioimmunoconjugates

Long-Acting Recombinant IL-2

IL-2 Based Vaccines

CHAPTER 5 IL-2 WATCH FOR THESE DRUGS

CHAPTER 6 REFERENCES

List Of Tables

LIST OF TABLES

Table 1: Expression of CD25, CD122 and CD132 in Immune and Nonimmune Cells

Table 2: Selection of Clinical Studies With IL-2 Drugs at Different Doses on Different Targets

Table 3: IL-2 Agents to Watch

List Of Figures

LIST OF FIGURES

Figure 1: IL-2 Signaling Pathways and Their Primary Biological Effects in Different Immune Cell Types

Figure 2: Three Different Types of IL-2 Receptors

Figure 3: Balancing Efficacy and Safety

Figure 4: Drugs Targeting IL-2

Figure 5: Computer Model of Neoleukin-2/15 Structure

I would like to order

Product name: Interleukin-2, a Tale of Two Halves: To Suppress or Augment Suppression, That is the Question

Product link: <https://marketpublishers.com/r/I5AE2F910EDEN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I5AE2F910EDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

